BiotechTube

Odevixibat + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome

Trial Timeline

Mar 19, 2021 → Sep 9, 2022

NCT ID
NCT04674761

About Odevixibat + Placebo

Odevixibat + Placebo is a phase 3 stage product being developed by Ipsen for Alagille Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04674761. Target conditions include Alagille Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04674761Phase 3Completed
NCT04336722Phase 3Active

Competing Products

9 competing products in Alagille Syndrome

See all competitors
ProductCompanyStageHype Score
OdevixibatIpsenPhase 3
74
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
maralixibatMirum PharmaceuticalsPre-clinical
20
Livmarli + LivmarliMirum PharmaceuticalsPre-clinical
20
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
LUM001 (Maralixibat) + PlaceboMirum PharmaceuticalsPhase 2
49
Livmarli Oral ProductMirum PharmaceuticalsApproved
82
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82